In April 2020, selumetinib, an oral selective MEK inhibitor that reduces PN size without serious adverse reactions in pediatric patients, was approved by the US Food and Drug Administration for the treatment of children with NF1-related progressive, inoperable plexiform neurofibroma [8,9,18,19,20,21,22]. This evidence concerns the gene NF1 and plexiform neurofibroma.